Persistent increase of cardiovascular and cerebrovascular events in COVID-19 patients : a 3-year population-based analysis
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com..
AIM: We evaluated the incidence and relative risk of major post-acute cardiovascular consequences of SARS-CoV-2 infection in a large real-world population from a primary care database in a region at moderate cardiovascular risk followed up in the period 2020-2022.
METHODS AND RESULTS: This is a retrospective cohort analysis using data from a cooperative of general practitioners in Italy. Individuals aged >18 affected by COVID-19 starting from January 2020 have been followed for three years. Anonymized data from of 228,266 patients in the period 2020-2022 were considered for statistical analysis and included 31,764 subjects with a diagnosis of COVID-19. An equal group of subjects recorded in the same database in the period 2017-2019 was used as propensity score matched comparison as an unquestionable COVID-19 free population. Out of the 228,266 individuals included in the COMEGEN Database during 2020-2022, 31,764 (13.9%) were ascertained positive with SARS-CoV-2 infection by a molecular test reported to general practitioners. The proportion of individuals with a new diagnosis of major adverse cardiovascular and cerebrovascular events was higher in the 2020-2022 COVID-19 group than in the 2017-2019 COMEGEN propensity score matched comparator, with an OR of 1.73 (95% CI: 1.53-1.94; p<0.001). All major adverse cardiovascular and cerebrovascular events considered showed a significantly higher risk in COVID-19 individuals. Incidence calculated for each 6-months period after the diagnosis of COVID-19 in our population was the highest in the first year (1.39 and 1.45% respectively), though it remained significantly higher than in the COVID-19 free patients throughout the three years.
CONCLUSIONS: The increase of cardiovascular risk associated with COVID-19 might be extended for years and not limited to the acute phase of the infection. This should promote the planning of longer follow up for COVID-19 patients to prevent and promptly manage the potential occurrence of major adverse cardiovascular and cerebrovascular events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cardiovascular research - (2024) vom: 19. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Allegra, Battistoni [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atrial fibrillation |
|---|
| Anmerkungen: |
Date Revised 19.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/cvr/cvae049 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369912233 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369912233 | ||
| 003 | DE-627 | ||
| 005 | 20240319233732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cvr/cvae049 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM369912233 | ||
| 035 | |a (NLM)38501586 | ||
| 035 | |a (PII)cvae049 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Allegra, Battistoni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistent increase of cardiovascular and cerebrovascular events in COVID-19 patients |b a 3-year population-based analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. | ||
| 520 | |a AIM: We evaluated the incidence and relative risk of major post-acute cardiovascular consequences of SARS-CoV-2 infection in a large real-world population from a primary care database in a region at moderate cardiovascular risk followed up in the period 2020-2022 | ||
| 520 | |a METHODS AND RESULTS: This is a retrospective cohort analysis using data from a cooperative of general practitioners in Italy. Individuals aged >18 affected by COVID-19 starting from January 2020 have been followed for three years. Anonymized data from of 228,266 patients in the period 2020-2022 were considered for statistical analysis and included 31,764 subjects with a diagnosis of COVID-19. An equal group of subjects recorded in the same database in the period 2017-2019 was used as propensity score matched comparison as an unquestionable COVID-19 free population. Out of the 228,266 individuals included in the COMEGEN Database during 2020-2022, 31,764 (13.9%) were ascertained positive with SARS-CoV-2 infection by a molecular test reported to general practitioners. The proportion of individuals with a new diagnosis of major adverse cardiovascular and cerebrovascular events was higher in the 2020-2022 COVID-19 group than in the 2017-2019 COMEGEN propensity score matched comparator, with an OR of 1.73 (95% CI: 1.53-1.94; p<0.001). All major adverse cardiovascular and cerebrovascular events considered showed a significantly higher risk in COVID-19 individuals. Incidence calculated for each 6-months period after the diagnosis of COVID-19 in our population was the highest in the first year (1.39 and 1.45% respectively), though it remained significantly higher than in the COVID-19 free patients throughout the three years | ||
| 520 | |a CONCLUSIONS: The increase of cardiovascular risk associated with COVID-19 might be extended for years and not limited to the acute phase of the infection. This should promote the planning of longer follow up for COVID-19 patients to prevent and promptly manage the potential occurrence of major adverse cardiovascular and cerebrovascular events | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a cardiovascular disease recovery | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 4 | |a stroke | |
| 650 | 4 | |a viral infection | |
| 700 | 1 | |a Massimo, Volpe |e verfasserin |4 aut | |
| 700 | 1 | |a Carmine, Morisco |e verfasserin |4 aut | |
| 700 | 1 | |a Gaetano, Piccinocchi |e verfasserin |4 aut | |
| 700 | 1 | |a Roberto, Piccinocchi |e verfasserin |4 aut | |
| 700 | 1 | |a Massimo, Fini |e verfasserin |4 aut | |
| 700 | 1 | |a Stefania, Proietti |e verfasserin |4 aut | |
| 700 | 1 | |a Stefano, Bonassi |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Trimarco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular research |d 1967 |g (2024) vom: 19. März |w (DE-627)NLM000080209 |x 1755-3245 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cvr/cvae049 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 03 | ||